Followers | 11 |
Posts | 190 |
Boards Moderated | 0 |
Alias Born | 06/28/2017 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, September 12, 2018 7:28:20 AM
Gilead, Galapagos' experimental drug filgotinib hits main goal of Phase III study in rheumatoid arthritis
Bristol-Myers Squibb reports promising mid-stage data for TYK2 inhibitor in plaque psoriasis
Foamix moves closer to US filing for acne treatment FMX101 after late-stage study success
Takeda to move US headquarters in Deerfield to Massachusetts
Merck KGaA, Pfizer say combination of Bavencio, Inlyta improves PFS versus Sutent in kidney cancer study
Merck & Co. set to seek EU, US approval of Zerbaxa for pneumonia after late-stage study hits goals
In The Know: Analyst answers — Are changes coming to the way we treat MS?
ViewPoints: Bristol-Myers Squibb's oral play in psoriasis slowly coming into focus
In June, Bristol-Myers Squibb began enrolling the first of two pivotal-stage studies for its TYK2 inhibitor BMS 986165 in psoriasis and this week the company will present the Phase II data that supported this decision at the European Academy of Dermatology and Venereology (EADV) meeting.
Key opinion leaders (KOLs) have identified TYK2 inhibitors as a potentially valuable new class of therapy, which administered orally could compete with Celgene's Otezla for the treatment of plaque psoriasis. The stakes are raised further with Bristol-Myers Squibb choosing to select Otezla as an active control arm in one of its recently initiated Phase III studies.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM